84138-74-9

Upstream product

• 119869-02-2 2-{[(2-chlorophenyl)oxy]acetyl}hydrazinecarbothioamide 
• 36304-40-2 (2-chlorophenoxy)acetic acid hydrazide 
• 614-61-9 (2-chlorophenoxy)acetic acid 
• 95-57-8 2-monochlorophenol 
• 79-19-6 thiosemicarbazide 

Downstream Products

• 1052695-03-0 1,1-dimethylethyl 6-{[(5-{[(2-chlorophenyl)oxy]methyl}-1,3,4-thiadiazol-2-yl)amino]carbonyl}-3,4-dihydro-2(1H)-isoquinolinecarboxylate 
• 1246434-90-1 2-[(2-chlorophenoxy)methyl]-5-chloro-1,3,4-thiadiazole 
• 1227624-41-0 C₁₀H₈ClN₃O₂S 
• 1345699-67-3 C₉H₆ClIN₂OS 
• 1345699-69-5 C₉H₆BrClN₂OS 
• 1357853-68-9 C₁₇H₁₂ClN₃OS 
• 1357853-50-9 C₂₂H₂₁ClN₄O₂S 
• 1052693-67-0 N-(5-{[(2-chlorophenyl)oxy]methyl}-1,3,4-thiadiazol-2-yl)-2-propyl-1,2,3,4-tetrahydro-6-isoquinolinecarboxamide 
• 1052693-62-5 N-(5-{[(2-chlorophenyl)oxy]methyl}-1,3,4-thiadiazol-2-yl)-2-(hydroxyacetyl)-1,2,3,4-tetrahydro-6-isoquinolinecarboxamide 
• 1052696-08-8 1,1-dimethylethyl 6-{[(5-{[(2-chlorophenyl)oxy]methyl}-1,3,4-thiadiazol-2-yl)(methyl)amino]carbonyl}-3,4-dihydro-2(1H)-isoquinolinecarboxylate 
• 1052693-65-8 N-(5-{[(2-chlorophenyl)oxy]methyl}-1,3,4-thiadiazol-2-yl)-2-(phenylcarbonyl)-1,2,3,4-tetrahydro-6-isoquinolinecarboxamide 
• 1052693-68-1 N-(5-{[(2-chlorophenyl)oxy]methyl}-1,3,4-thiadiazol-2-yl)-2-[5-(hydroxymethyl)-1,3-thiazol-2-yl]-1,2,3,4-tetrahydro-6-isoquinolinecarboxamide 
• 1052693-61-4 N-(5-{[(2-chlorophenyl)oxy]methyl}-1,3,4-thiadiazol-2-yl)-N-methyl-1,2,3,4-tetrahydro-6-isoquinolinecarboxamide hydrochloride 
• 1052692-95-1 N-(5-{[(2-chlorophenyl)oxy]methyl}-1,3,4-thiadiazol-2-yl)-1,2,3,4-tetrahydro-6-isoquinolinecarboxamide hydrochloride 

Relevant academic research and scientific papers

Synthesis, evaluation and in silico molecular modeling of pyrroyl-1,3,4-thiadiazole inhibitors of InhA

Enoyl acyl carrier protein reductase (ENR) is an essential type II fatty acid synthase (FAS-II) pathway enzyme that is an attractive target for designing novel antitubercular agents. Herein, we report sixty-eight novel pyrrolyl substituted aryloxy-1,3,4-thiadiazoles synthesized by three-step optimization processes. Three-dimensional quantitative structure-activity relationships (3D-QSAR) were established for pyrrolyl substituted aryloxy-1,3,4-thiadiazole series of InhA inhibitors using the comparative molecular field analysis (CoMFA). Docking analysis of the crystal structure of ENR performed by using Surflex-Dock in Sybyl-X 2.0 software indicates the occupation of pyrrolyl substituted aryloxy 1,3,4-thiadiazole into hydrophobic pocket of InhA enzyme. Based on docking and database alignment rules, two computational models were established to compare their statistical results. The analysis of 3D contour plots allowed us to investigate the effect of different substituent groups at different positions of the common scaffold. In vitro testing of ligands using biological assays substantiated the efficacy of ligands that were screened through in silico methods.

Synthesis and xanthine oxidase inhibitory activity of 7-methyl-2- (phenoxymethyl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one derivatives

An elevated level of blood uric acid (hyperuricemia) is the underlying cause of gout. Xanthine oxidase is the key enzyme that catalyzes the oxidation of hypoxanthine to xanthine and then to uric acid. Allopurinol, a widely used xanthine oxidase inhibitor is the most commonly used drug to treat gout. However, a small but significant portion of the population suffers from adverse effects of allopurinol that includes gastrointestinal upset, skin rashes and hypersensitivity reactions. Moreover, an elevated level of uric acid is considered as an independent risk factor for cardiovascular diseases. Therefore use of allopurinol-like drugs with minimum side effects is the ideal drug of choice against gout. In this study, we report the synthesis of a series of pyrimidin-5-one analogues as effective and a new class of xanthine oxidase inhibitors. All the synthesized pyrimidin-5-one analogues are characterized by spectroscopic techniques and elemental analysis. Four (6a, 6b, 6d and 6f) out of 20 synthesized molecules in this class showed good inhibition against three different sources of xanthine oxidase, which were more potent than allopurinol based on their respective IC50 values. Molecular modeling and docking studies revealed that the molecule 6a has very good interactions with the Molybdenum-Oxygen-Sulfur (MOS) complex a key component in xanthine oxidase. These results highlight the identification of a new class of xanthine oxidase inhibitors that have potential to be more efficacious, than allopurinol, to treat gout and possibly against cardiovascular diseases.

Synthesis of some new 2-aryloxymethyl-1,3,4-thiadiazolo[2,3-b]quinazol-4-ones as antifungal agents

Some quinazolones derivatives of 2-aryloxymethyl-1,3,4-thiadiazolo-[3,2-b]quinazol-4-one have been synthesized and assayed for their possible antifungal activity against Alternaria porri and Helminthosporium oryzae and were compared with standard drug carbendazim. Some of the compounds show notable activity. The structures of these compounds have been elucidated by IR, NMR and elemental analysis.

Synthesis and biological evaluation of some novel 2-mercaptobenzothiazoles carrying 1,3,4-oxadiazole, 1,3,4-thiadiazole and 1,2,4-triazole moieties

Several 2-mercaptobenzothiazole derivatives containing 1,3,4-oxadiazoles, 1,2,4-triazoles and 1,3,4-thiadiazoles at the second position were synthesized. Some of these synthesized compounds were evaluated for their in vivo analgesic, anti-inflammatory, acute toxicity and ulcerogenic actions. Some of the tested compounds showed significant analgesic and anti-inflammatory activities. Two of the compounds showed significant gastrointestinal protection compared to the standard drug diclofenac sodium. The compounds were also tested for their in vitro antimicrobial activity with most displaying selective activity against the Gram-negative bacteria Pseudomonas aeruginosa. In the present investigation the tested compounds did not possess antifungal activity.

Synthesis of 2-(N-formyl)-5-aryl/aryloxymethyl-1,3,4-thiadiazoles with potential bioactivity in PEG-400

An environmental benign procedure for synthesis of 2-(N-formyl)-5-aryl/aryloxymethyl-1,3,4-thiadiazoles has been developed by reaction of 2-amino-5-aryl/aryloxymethyl-1,3,4-thiadiazoles with formic acid in PEG-400. The key advantages of this protocol are

SUBSTITUTE 1, 6-NAPHTHYRIDINES FOR USE AS SCD INHIBITORS

The present invention relates to substituted tetrahydronaphthyridine (THN) compounds of the formula (I) and salts thereof, to pharmaceutical compositions containing them and their use in medicine. In particular, the invention relates to compounds for inhibiting SCD activity.

THIADIAZOLE DERIVATIVES, INHIBITORS OF STEAROYL-COA DESATURASE

The present invention relates to substituted thiadiazole compounds of the formula (I) and pharmaceutically acceptable salts thereof, to pharmaceutical compositions containing them and their use in medicine. In particular, the invention relates to compounds for modulating SCD activity.

Polymer-supported dichlorophosphate: A recoverable new reagent for synthesis of 2-amino-1,3,4-thiadiazoles

Poly(ethylene glycol) (PEG) supported dichlorophosphate was efficiently used as a recoverable new dehydration reagent for rapid synthesis of 2-amino-5-substituted-1,3,4-thiadiazoles under microwave irradiation and solvent-free condition by reactions of thiosemicarbazide with aliphatic acids, benzoic acid, aryloxyacetic acids or furan-2-carboxylic acids.